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We have conducted short-term and prolonged studies in normal men and 
in diabetic subjects to compare the physiological properties of chlorpropamide 
and tolbutamide. The primary objectives of the investigation were: first, 
to correlate the hypoglycemic effect with the serum sulfonylurea level for 
each compound; and, second, to compare the rates of disappearance of the 
two drugs from the blood. In  addition, we performed metabolic balance 
studies in two normal men during the administration of chlorpropamide. 
Methods 
Serum concentrations of both chlor- 
propamide and tolbutamide were determined by the same analytical method. 
This method, developed by Toolan and Wagner for chlorpropamide, and 
described elsewhere in this monograph, was found to serve equally well for 
the determination of tolbutamide. 
The performance of the method in this laboratory is summarized in TABLE 1. 
S e r u m  sulfonylurea determinations. 
TABLE 1 
PERFORMANCE OF THE ANALYTIC METHOD IN THE DETERMINATION OF SERUM 
CHLORPROPAMIDE AND TOLBUTAMIDE CONCENTRATIONS 
Recovery of the sailjonylureas from serum: 
Chlorpropamide 97 0 t 1 2% 
Tolbu tamide 9 9 0 + 0 8 %  
Features of the method: 
Reproducibility (standards) 
k0.25 mg./100 ml. sulfonylurea 
Precision (intraset serum replicates) 
t0.13 mg./100 ml. sulfonylurea 
Accuracy (interset serum duplicates) 
kO.23 mg./100 ml. sulfonylurea 
Values represent mean and/or standard deviation. The indicated values were derived 
as follows: recovery, 6 prepared serum samples each for chlorpropainide and tolbutamide 
between the concentrations of 0 to 24 mg./100 ml.; reproducibility, variation of the mid- 
level standard in 35 sets; precision, variation among 9 intraset serum replicates; accuracy, 
variation among 30 serum samples, as 15 duplicate pairs with concentrations of 1 to 
35 mg./100 ml., scattered among 13 sets. 
The recovery of both sulfonylureas added to serum was essentially complete. 
* The work reported in this paper was supported in part by Chas. Pfizer & Co., Inc., 
Brooklyn, N. Y., and in part by Grant A888 C3 from the National Institute of Arthritis 
and Metabolic Diseases, Public Health Service, Bethesda, Md. 
t Investigator, the Howard Hughes Medical Institute, Miami Beach, Fla. 
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The method, which showed excellent reproducibility, allowed a precision of 
approximately 0.1 mg. per cent and an accuracy of approximately 0.25 mg. 
per cent in serum measurements of sulfonylurea. 
Addit.iona1 data relevant t o  the application of the serum sulfonylurea 
method are provided in TABLE 2. Chlorpropamide and tolbutamide, as well 
as tolbutamide and the tolbutamide metabolite, are interrelated in terms of 
their relative absorbance intensity in the method. A low serum “blank” 
value was found. 
T.~BI.E 2 
L)ATA RELEIANT TO THE .iPPLICATION O F  TIIE SERCJM S U L F O N Y L U K E A  . i N A L Y T l C A L  METlIOD 
Comparative (pantitation data: 
Relative absorbancy 
(on a weight basis) 
C hlorpropamide 100.0 - 
Tolbutaniide 83.8 100.0 
Tolh tamide  metabolite - 38.5 
Serum “blank” values (55 different serum samples from 
5 normal, 2 diabetic, and 2 other subjects; run in 22  sets) : 
Method not corrupted by: 
0.22 f 0.54 mg.ji00 ml. (as chlorproparnide) 
(1) Products from hemolysis 
(2) Existence of the tolbutamide metabolite 
Mean zk standard deviation given for serum blank values. 
The method is not corrupted by the products from hemolysis. Aliquots of 
2 different blood samples devoid of sulfonylurea were briskly beaten with 
wooden applicators while the blood was clotting. The resultant deeply pig- 
mented sera, when compared in analysis with nonhemolyzed “duplicates,” 
were found to have increased in apparent sulfonylurea only by about 0.4 mg. 
per cent. The degree of hemolyiis produced deliberately in this evaluation 
was approximately 10 times greater than any experienced throughout the 
inve5tigation being described. Mention is made of this observation con- 
cerning hemolysis, since plasma and serum tolbutamide methods in current 
ube have a demonstrated’ or likely2-’ sensitivity to corruption by the products 
from hemolysis. 
A4s an important consideration, the sulfonylurea method used in our studies 
i5 not corrupted by the existence of the tolbutamide metabolite5 (l-butyl- 
3-p-carboxyphenylsulfonylurea). The metabolic half life of the tolbutamide 
metabolite was determined by techniques similar to those described below 
for tolbutamide. It was found to be approximately 9 times (8.6) shorter than 
the metabolic half life of tolbutamide. The metabolite thus disappears 
from blood approximately 9 times faster than tolbutamide and exhibiti 
absorbancy approximately 2?5 times less than tolbutamide in this method 
(TABLE 2). I t  is unlikely, therefore, that measured serum iulfonylurea 
kevels, after tolbutamide administration, could be more than about 1 per cent 
in  error because of the presence of the metabolite. 
Fasting blood glucose; serum sodium, potassium, 
and chloride; and urinary nitrogen, creatinine, sodium, potassium, chloride, 
Other determinations. 
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17-hydroxycorticoids, and 17-ketosteroids were determined by methods 
previously used in this laboratory.6 
Two normal and 2 diabetic subjects were admitted to the 
Metabolism Research Laboratory and maintained on constant diets. The 
2 normal subjects (R. R., male, age 23, 70 kg.; and J. D., male, age 20,69 kg.) 
received a diet that  provided 200 mEq. sodium, 113 mEq. potassium, 17.3 gm. 
nitrogen, 320 gm. carbohydrate, and 2900 calories per day. One diabetic 
patient (A. R., female, age 62, 87 kg.) received 178 gm. carbohydrate and 
2150 calories per day; the other (R. B., female, age 63, 73 kg.) received 150 
gm. carbohydrate and 1400 calories per day. 
Eleven diabetic patients, chosen because they responded poorly to tolbut- 
amide, were studied in the Endocrinology and Metabolism Out-Patient Clinic 
of the University Medical Center. 
Results 
Meas- 
urements of chlorpropamide or tolbutamide disappearance from blood were 
made after intravenous administration of each compound. The series 
included observations on 2 normal and 2 diabetic subjects. After an over- 
night fast each subject received chlorpropamide or tolbutamide sodium* 
(30 mg./kg.) a t  8:OO A.M., and food was withheld for 6 hours. 
I t  is seen 
that the chlorpropamide serum concentration declined from about 21 mg. 
per cent a t  15 min. to about 18 mg. per cent a t  6 hours, whereas the tolbut- 
amide serum concentration fell more rapidly from about 20 mg. per cent a t  
15 min. to about 8 mg. per cent a t  6 hours. The serum chlorpropamide 
concentration continued to decline slowly, and the serum tolbutamide con- 
centration fell much more rapidly. The 2 drug levels extrapolated to zero 
concentration a t  18 hours for tolbutamide and a t  145 hours for chlorprop- 
amide. Thus, under the circumstances of this experiment, tolbutamide dis- 
appeared from the blood approximately 8 times faster than chlorpropamide. 
I t  is of interest to note (FIGURE 1) that there was no significant difference 
between the nature and degree of the acute hypoglycemia produced by the 
2 drugs a t  this dosage level. Such was the case even though the tolbutamide 
serum concentration had fallen rapidly as compared with that of chlorprop- 
amide. As would be anticipated, there was no correlation between the 
serum drug levels and the blood glucose levels in these acute (6-hour) experi- 
ments. I t  is likely that under these conditions hypoglycemia was maximally 
induced when the serum sulfonylurea levels (after the administration of 
either drug) were above 20 mg. per cent for 15 min., 18 mg. per cent for 
30 min., or 17 rng. per cent for 45 min. Reversal of the progressive hypo- 
glycemia a t  about 45 min. was undoubtedly the result of effective counter- 
action through physiological mechanisms that function to normalize the 
concentration of blood glucose. 
This subject had 
Tolbutamide 
Subjects. 
T h e  disappearance of chlorpropamide and tolbutamide from the blood. 
Data for one of the normal subjects are presented in FIGURE 1. 
FIGURE 2 shows data for one of the diabetic subjects. 
* Chlorpropamide was supplied by 1). Iezzoni, Chas. Pfizer & Co., Inc. 
was supplied by C. J. O’Donovan, The Upjohn Co., Kalamazoo, Mich. 
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somewhat higher serum sulfonylurea levels during the study. The higher 
serum levels probably resulted from the fact that the dose administered was 
based upon gross body weight, and also from the fact that this subject was 
moderately obese. Another notable characteristic of the sulfonylurea dis- 
appearance curves, in this case, is the marked difference between the chlor- 
propamide and tolbutamide serum levels. Since the disappearance rates 
for the 2 drugs were very similar and quite constant during the interval from 
10 through 60 min., the early difference in serum concentrations probably 
reflects a difference in distribution space for the 2 drugs. 
In  spite of the higher serum levels and the initial differential between the 
curves, the disappearance rates for chlorpropamide and tolbutamide in this 
diabetic subject were quite similar to those for the previous normal subject 
(FIGURE 1). I t  should be noted that this diabetic subject, as well as the 
other one in the series, was previously treated with both sulfonylurea com- 
pounds. The administration of chlorpropamide to both diabetic subjects 
was discontinued 9 days before these studies began. 
I n  the diabetic subject (FIGURE 2) there were almost identical progressive 
reductions in blood sugar after intravenous administration of equal quantities 
of the 2 drugs. It is impressive that these acute blood glucose responses 
were remarkably similar in spite of the great difference that had developed 
in the serum sulfonylurea concentrations by 6 hours. These results are 
consistent with those obtained in the normal subject, and they suggest 
that the pattern for the blood glucose response was determined a t  an early 
time when the serum sulfonylurea concentration for each compound was 
sufficiently high to induce a maximal response. 
In  the other 2 subjects, the second normal and the second diabetic, there 
was also no significant difference in the acute blood glucose responses after 
intravenous administration of the indicated amounts of chlorpropamide 
and tolbutamide. The sulfonylurea disappearance rates for both of these 
subjects were very similar to those already illustrated (FIGURES 1 and 2). 
A more detailed graphic evaluation of the disappearance rates of chlor- 
propamide and tolbutamide was made for each of the 4 subjects. Such an  
evaluation is illustrated in FIGURE 3 for one of the diabetic subjects. The 
disappearance rate is expressed as metabolic half life (t44) which, conven- 
tionally, is defined as the time required for the serum concentration to decline 
to one half of a previous level. 
I t  is seen that after chlorpropamide administration a t  zero time there 
occurs a very rapid decrease in the serum concentration during the first 
10 min. (first 2 dots, a t  5 and 10 rnin.). A rapid decline in serum concen- 
tration follows so that the metabolic half life of chlorpropamide during the 
time interval from 15 through 45 min. is calculated to be 2.8 hours. At 
about the first hour the serum concentration of chlorpropamide stabilizes 
and remains essentially unchanged up to the sixth hour. During this 5-hour 
period the half life of chlorpropamide is described, of course, as infinite. 
After this plateau phase, the half-life time fluctuates considerably until 
about 36 hours, when a terminal steady-state disappearance begins. During 
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this  phase of terminal steady-state disappearance (36 to 144 hours) chlor- 
propamide is calculated to have a metabolic half life of 35 to 36 hours. 
'I'he disappearance of tolbutamide (FIGURE 3), after its intravenous adniin- 
istration, can be described also in rate phases. The three indicated phases 
for tolbutamide represent half life times of 3.3, 4.9, and 3.8 hours. 
The phases which have been described in this subject for chlorpropamide 
and tolbutamide by half life calculations were also obierved in the second 
diabetic and in both normal subjects. The simplest interpretation which 
ran account for the phases observed after intravenous administration of eaLh 
compound is: (1) an early (0 to 60 min.) unstable space distribution; (2) a 
rediitribution (1 to 36 hours for chlorpropamide, 1 to 6 hours for tolbut- 
amide), and ( 3 )  a stable space distribution (> 36 hours for chlorpropamide, 
- 
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FIGURE 3.  Metabolic half-life times lor chlorpropamide and tolbutamide in a tliahetic 
suhject (-4. K., female). 
> 6 hours for tolbutamide). It would be extremely interesting to make 
space-distribution calculations for strategic timings in such an experimental 
series as this. Since our studies did not extend to drug balance (excretory 
studies), this was not possible for these subjects. It was interesting, how- 
ever, to make initial or zero-time calculations of space distribution in a 
comparison of the 2 drugs. Extrapolation from the 5- and 10-min. points, 
in the 2 diabetic subjects gave chlorpropamide space volumes of 7.6 and 
6.0 I.  and tolbutamide space volumes of 9.0 and 9.3 I.  'The mean chlorprop- 
amide and tolbutamide spaces in these 2 diabetics were 9 and 11 per cent 
of body weight, respectively. 
The difference between mean values of 7.3 and 9.2 I .  for chlorpropamide 
and tolbutamide spaces, respectively, would seem highly significant in these 
2 subjects. From preliminary studies of deliberate blood sample hemolysis 
after chlorpropamide and tolbutamide administration it appears that the 
different space distributions of these 2 drugs may be explainable, to a major 
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were used to arrive a t  a comparison of the rates of disappearance of these 
2 drugs from the blood. This comparison is given as a ratio calculation 
below TABLE 3 and indicates that  tolbutamide disappears from the blood from 
7 to 8 times faster than chlorpropamide. 
I t  was clear that 
acute studies and classic dose-response studies would yield information of 
limited value in a potency comparison of chlorpropamide and tolbutamide, 
especially if one attempted to apply such information in terms of long-term 
oral therapy. On the other hand, it appeared as though meaningful data 
T h e  relative potency of chlorpropamide aizd tolbutamide. 
FIGURE 4. Fasting blood glucose and fasting serum sulfonylurea levels in 2 normal men 
during the administration of chlorpropamide and tolbutamide. 
could be derived from long-term comparisons of the 2 drugs a t  various 
dosage levels and from a separation of the classic dose-response study into 
2 distinct components: the relation of dose to drug blood level and the relation 
of drug blood level to blood glucose response. Such an approach would 
take into account the facts that:  (1) the 2 drugs had markedly different 
half-life times, and (2) the 2 drugs probably had different spaces of dis- 
tribution. With these consideration5 in mind, 2 normal men were studied 
for a period of about 4 weeks on an identical schedule of changing doses of 
oral chlorpropamide (FIGURE 4). During this period the men were carried 
through 2 cycles of symptomatic hypoglycemia. In  a subsequent period 
they were observed during episodes of tolbutamide-induced hypoglycemia. 
Much larger oral dosages of tolbutamide (at least 6 times larger) were 
required to produce comparable hypoglycemia and comparable serum sul- 
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fonylurea levels. Daily measurements of the fasting blood glucose and the 
fasting serum sulfonylurea levels during oral administration of the 2 drugs 
revealed a consistent pattern. 
In FIGURE 5 the fasting serum sulfonylurea levels are plotted against 
changes in the fasting blood glucose levels for the 2 normal men. Standard 
FASTING SERUM SULFONYLUREA 
( M  G./100 ML.) 
FIGURE 5. Correlation between change in fasting blood glucose and fasting serum 
deviations relate to both men for daily fasting blood glucose measurements 
during an 8-day pretest period. The curve was originally constructed in 
the absence of the tolbutamide points, with reference only to the chlor- 
propamide points. It is apparent, however, that when the tolbutamide 
points are included, as they are in this figure, they fit the previously con- 
structed curve for chlorpropamide. These results indicate that, within the 
standardizations and extensiveness of these observations, chlorpropamide 
sulfonylurea levels in 2 normal suhjects. 
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and tolbutamide are equally active, on the basis of serum concentrations, as 
agents to produce change in the blood glucose concentration. 
'2 serum sulfonylurea level of about 12 mg. per cent was required to pro- 
duce a decrease of 1 standard deviation in the fasting blood glucose in these 
normal men. A decrease of twice the standard deviation in the fasting 
blood glucose resulted from a serum sulfonylurea level of about 15 mg. per 
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cent. All sulfonylurea levels above 18.5 mg. per cent produced decreases 
in the fasting blood glucose of a t  least twice the standard deviation. Within 
the range of significant measurements, increments in serum sulfonylurea 
concentration of approximately 3 mg. per cent double the effect on the fasting 
blood glucose. 
The data from FIGURE 5 are reproduced in FIGURE 6 with semilogarithmic 
coordinates. Under this circumstance the relationship between the fasting 
serum sulfonylurea level and the change in the fasting blood glucose is repre- 
sented by a straight line. 
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Since chlorpropamide and tolbutamide, on the basis of their serum con- 
centrations, are approximately equally active, and since tolbutamide disap- 
pears from the blood approximately 8 times faster than chlorpropamide, it 
follows that chlorpropamide has the potentiality of being approximately 
8 times more effective than tolbutamide, on a weight basis, when the 2 drugs 
are used as oral therapeutic agents. 
I t  was of interest to obtain information on how the serum chlorpropamide 
concentration varies during a 24-hour period when 500 to 750 mg. is adminis- 
tered each morning with breakfast (TABLE 4). Although the 2 subjects had 
TABLE 4 
ORAL MORNING DOSES OF THE DRUG IN 2 NORMAL MEN 
VARIATION OF SERUM CHLORPROPAMIDE LEVELS DURING THE DAY AFTER SINGLE 
Subject 
R. R. (70 kg.) 
---_____ 
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* Days correspond with those in FIGURE 4. 
t Total dose taken shortly after 8:OO A.M. with breakfast. 
very similar fasting serum chlorpropamide concentrations on the same drug 
dosages, they showed somewhat different but quite consistent variations in 
serum levels during the intervals studied. The subjects developed maximum 
serum chlorpropamide concentrations of 123 and 157 per cent of the fasting 
levels about 4 hours after an oral dose a t  8:OO A.M.  The serum levels a t  
5:OO P.M. were 103 and 121 per cent of the morning fasting levels even when 
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Thus, a single do5e of chlorpropamide a t  8:OO A.M. would seem to provide 
elevated serum sulfonylurea levels (that is, relative to the fasting level) during 
the absorptive portion of the day (about 8:OO A.M.  to 8:OO P.M.) and to allow 
the serum level to decline to a near-fasting level early in the usually non- 
absorptive portion (about 8:OO F.M. to 8:OO A.M.) of the day. This feature, 
which is provided by the long metabolic half-life time of chlorpropamide, 
may prove to be advantageous therapeutically. 
Eleven diabetic patients who responded poorly to tolbut- 
amide were treated with chlorpropamide. All responded better to chlor- 
propamide a t  coniiderably lower daily dosages in most cases. 
The comparative response of the 11 diabetic patients to the 2 compounds is 
illustrated in TABLE 5 .  Each patient received each substance, a t  the indi- 
cated dosages, for a t  least 3 days and usually for 1 week prior to the deter- 
minations. Complete comparative data were obtained for the first 3 patient5 
Clinical studieJ. 
TABLE 5 
C'OMI'ARATI\ E KEWONSE OF PATIENTS WITH DIABETES MFLLITIJ~ TO O ~ A I  
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A. R. (95 kn.) .  . 
E. E. (74 k g . ) .  . 
H. H. (60 k a . ) .  .
R. €3. (73 kg . ) .  . 
A. C .  (58 kg.) 
P. F. (5.5 kg.).  . 
I(. H. (72 kg. ) .  . 
S. J .  (107  kg . ) .  , 
M. K. (88 ke.). . 
P. S. (41 kgy): . . 
S .  M .  (75 kr.) 
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listed. The decreases in the fasting blood glucose levels experienced by 
these 3 patients on the indicated tolbutamide dosages were slight. The 
relatively low fasting serum tolbutamide levels are to be noted. In the 
same 3 patients considerably lower dosages of chlorpropamide produced 
higher serum levels of the drug and, concurrently, more intense decreases 
of the fasting blood glucose levels. The same pattern of response described 
for the first 3 patients is characteristic of the other 8, as well. 
The data presented for these 11 diabetic patients are consistent with the 
hypothesis that neither drug is intrinsically more effective than the other, and 
that the greater clinical efficacy of chlorpropamide, as compared with tol- 
hutamide, is due t o  its longer metabolic half life. The longer metabolic 
half life (that is, the slower disappearance from the blood) enables the produc- 
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An example of the difference in response to the 2 drugs is illustrated in 
Melabolic balmce studies. Two normal men were studied for a period of 
about 4 weeks on an identical schedule of changing doses of chlorpropamide. 
The balance and renal excretion studies (TABLE 6) during chlorpropamide 
administration yielded results similar to those previously published from 
this laboratory for tolbutamide and carbutamide.6 
There were 110 significant changes from control averages, for the mean uri- 
nary excretion of nitrogen, creatinine, electrolytes, 17-hydroxycorticoids, and 
17-ketosteroids, while on chlorpropamide. However, on several individual 
FIGURE 7. 
I i ~ ~ ~ ~ ~  7. Fasting blood glucose and fasting serum sulfonylurea levels in a diabetic 
whject during the administration of tolbutamide and chlorpropamide. 
days when severe symptomatic hypoglycemia had been produced , urinary 
excretion of nitrogen and electrolytes was significantly decreased, and the 
excretion of 17-hydroxycorticoids was increased. Serum levels of sodium, 
potassium, and chloride likewise were not affected. 
Summary a i d  Co-lzclusions 
(1) A single analytical method has been found to perform well for the 
determination of both chlorpropamide and tolbutamide in serum. 
(2) Evidence has been presented from long-term studies to indicate that, 
on the basis of serum concentrations, chlorpropamide and tolbutamide are 
approximately equally active in normal men. 
( 3 )  Tolbutamide disappears from the blood of normal men and diabetic 
subjects approximately 8 times faster than does chlorpropamide. 
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(4) Chlorpropamide, when compared with tolbutamide on a weight basis, 
exhibits a markedly greater clinical effectiveness. 
( 5 )  The greater clinical efficacy observed with chlorpropamide seems ade- 
quately explainable on the basis of the capacity of the drug to produce and 
maintain higher serum levels on a given dosage schedule. 
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